Online Database of Chemicals from Around the World

N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine
[CAS# 796073-69-3]

List of Suppliers
BrightGene Bio-medical Technology Co., Ltd. China Inquire
www.bright-gene.com
+86 (512) 6255-1801
6255-1767
+86 13812696362
+86 (512) 6255-1799
kevinwan@bright-gene.com
kevinwan0203@gmail.com
QQ Chat
Skype Chat
Chemical manufacturer since 2001
chemBlink Standard supplier since 2009
BOC Sciences USA Inquire
www.bocsci.com
+1 (631) 485-4226
+1 (631) 614-7828
info@bocsci.com
Chemical manufacturer
chemBlink Standard supplier since 2010
Hangzhou Leap Chem Co., Ltd. China Inquire
www.leapchem.com
+86 (571) 8771-1850
market19@leapchem.com
QQ Chat
Chemical manufacturer since 2006
chemBlink Standard supplier since 2015
Shanghai Min-biotech Co., Ltd. China Inquire
www.min-biotech.com
+86 15190045345
sales@min-biotech.com
Chemical manufacturer since 2017
chemBlink Standard supplier since 2024
Zhejiang Hisun Pharmaceutical Co., Ltd. China Inquire
www.hisunpharm.com
+86 13651899693
yiwen.sun@hisunpharm.com
Chemical manufacturer since 1956
chemBlink Standard supplier since 2024

Identification
ClassificationAPI >> Antineoplastic agents
NameN2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine
SynonymsMaytansine DM 4; DM 4; Ravtansine;[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[methyl-(4-methyl-4-sulfanylpentanoyl)amino]propanoate
Molecular StructureCAS # 796073-69-3, N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine
Molecular FormulaC38H54ClN3O10S
Molecular Weight780.37
CAS Registry Number796073-69-3
EC Number641-067-1
SMILESC[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)C)C)OC)(NC(=O)O2)O
Properties
SolubilityInsoluble (3.7E-4 g/L) (25 °C), Calc.*
Density1.29±0.1 g/cm3 (20 °C 760 Torr), Calc.*
Melting point185-187 °C (decomp)**
*Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (©1994-2015 ACD/Labs)
**Widdison, Wayne C.
Safety Data
Hazard Symbolssymbol symbol symbol symbol   GHS05;GHS06;GHS07;GHS08 Danger  Details
Risk StatementsH300-H301-H310-H311-H314-H315-H319-H331-H340-H360-H361-H371  Details
Safety StatementsP203-P260-P261-P262-P264-P264+P265-P270-P271-P280-P301+P316-P301+P330+P331-P302+P352-P302+P361+P354-P304+P340-P305+P351+P338-P305+P354+P338-P308+P316-P316-P318-P321-P330-P332+P317-P337+P317-P361+P364-P362+P364-P363-P403+P233-P405-P501  Details
Hazard Classification
up    Details
HazardClassCategory CodeHazard Statement
Germ cell mutagenicityMuta.1BH340
Skin corrosionSkin Corr.1BH314
Reproductive toxicityRepr.1BH360
Specific target organ toxicity - single exposureSTOT SE1H370
Acute toxicityAcute Tox.1H310
Acute toxicityAcute Tox.2H300
Acute toxicityAcute Tox.1H300
Acute toxicityAcute Tox.3H311
Skin irritationSkin Irrit.2H315
Acute toxicityAcute Tox.3H301
Acute toxicityAcute Tox.3H331
Eye irritationEye Irrit.2H319
Reproductive toxicityRepr.2H361
SDSAvailable
up Discovery and Applications
N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine, commonly referred to as DM4, emerged from research efforts in the late 1970s by scientists at Takeda Chemical Industries in Japan. It is a potent cytotoxic agent derived from maytansine, a compound initially isolated from the plant Maytenus serrata. Through chemical modifications of maytansine's structure, DM4 was synthesized with the aim of enhancing its anticancer properties while reducing systemic toxicity.

DM4 serves as the cytotoxic payload in ADCs, a class of targeted cancer therapies. In ADCs, DM4 is conjugated to monoclonal antibodies specific to antigens expressed on the surface of cancer cells. Upon binding to the target antigen, the ADC is internalized into the cancer cell, where DM4 is released and exerts its cytotoxic effects. This targeted delivery minimizes systemic toxicity and enhances the therapeutic index of DM4, making it an attractive option for cancer treatment.DM4-based ADCs have demonstrated efficacy in the treatment of solid tumors, including breast cancer, gastric cancer, and bladder cancer. ADCs such as trastuzumab deruxtecan (DS-8201) utilize DM4 as the cytotoxic payload and have shown promising results in clinical trials. DM4-based ADCs have also shown promise in the treatment of hematological malignancies. Several ADCs targeting different antigens expressed on hematological cancer cells, such as CD30 and CD22, incorporate DM4 as the cytotoxic payload. These ADCs have demonstrated efficacy in the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, and acute lymphoblastic leukemia, among others.

References

2024. Synthesis and evaluation of antibody-drug conjugates with high drug-to-antibody ratio using dimaleimide-DM1 as a linker-payload. Bioorganic Chemistry, 149(1).
DOI: 10.1016/j.bioorg.2024.107504

2024. eSOMA-DM1, a Maytansinoid-Based Theranostic Small-Molecule Drug Conjugate for Neuroendocrine Tumors. Bioconjugate Chemistry, 35(10).
DOI: 10.1021/acs.bioconjchem.4c00413

1977. Tumor inhibitors. 122. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. The Journal of Organic Chemistry, 42(14).
DOI: 10.1021/jo00434a001
Market Analysis Reports
List of Reports Available for N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine
Related Products
N2'-Deacetyl-15...  O-Deacetylindac...  Deacetylinulici...  Deacetyl Iodixa...  4-Deacetyl-4-O-...  N-Deacetylketoc...  Deacetylkhayano...  Deacetyl (R)-Li...  Deacetyl Linezo...  De-N-acetyllyso...  N2'-Deacetyl-N2...  Deacetylmetaple...  2-De(Acetylmeth...  2-De(Acetylmeth...  (2E)-3-De[2-[Ac...  (2E)-3-De[2-[Ac...  O3-De2-(Acetylm...  10-Deacetyl-7-m...  N2'-Deacetyl-N2...  N(2')-Deacetyl-...